✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Journal · FDA oversight · dataset

Which GLP-1 Telehealth Companies Got FDA Warning Letters in 2026, and What Did FDA Object To?

Released: Last reviewed:

We counted every telehealth-tagged letter in FDA’s warning-letter index on November 20, 2026, read eight in full and matched the recipients against the programs we review.

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.
Direct answer

FDA’s warning-letter index, searched November 20, 2026, lists 56 letters issued in 2026 to telehealth companies under the subject “false & misleading claims / misbranded”: 30 dated February 20, 25 dated June 8 and one dated October 30. None shows a close-out letter, and every one we read concerns compounded GLP-1s. Recipients include NexLife, Eden, Belle and Maximus.

Takeaway: a warning letter is FDA’s formal notice of violations, not a recall, a ban or a court ruling. Look the company up yourself, read what FDA cited, and compare it with the program’s pages today.

This site reviews telehealth programs on what they disclose and how they are overseen, so FDA’s warning letters are part of the record we check. On November 20, 2026 we searched FDA’s public index for every letter whose subject is tagged “Telehealth”, counted them by date, read eight of them in full, and matched the recipients against the programs we cover. Here is what the record shows, and what it does not.

How many telehealth warning letters has FDA sent?

The index returned 114 letters tagged “Telehealth”. They fall into four dated batches. The first, 58 letters dated September 9, 2025, uses the subject “unlawful sale of unapproved and misbranded drugs to United States consumers over the internet” and went to companies selling a range of products; the Hims letter in that batch concerns compounded semaglutide. The other 56, all issued in 2026, use the subject “false & misleading claims / misbranded”: 30 dated February 20, 25 dated June 8 and one dated October 30.

Every 2026 letter we read concerns compounded semaglutide or tirzepatide. We did not read all 56, so we describe the batch by its FDA subject line rather than claim every letter is about GLP-1s. The index’s close-out column was empty for all 114 letters.

FDA warning letters tagged Telehealth, by date issued Bar chart from FDA's warning-letter index, searched November 20, 2026: 58 letters dated September 9, 2025 (internet sales of unapproved and misbranded drugs); 30 dated February 20, 2026, 25 dated June 8, 2026 and 1 dated October 30, 2026 (false or misleading claims). None has a close-out letter. FDA warning letters tagged “Telehealth”, by date issued Number of letters. Source: FDA warning-letter index, searched November 20, 2026. 0204060 5830251 Sep 9, 2025Feb 20, 2026Jun 8, 2026Oct 30, 2026 Internet sales of unapproved/misbranded drugs False or misleading claims
Original chart built from FDA’s warning-letter index (subjects ending in “(Telehealth)”), searched November 20, 2026. The same numbers are in the table below.
FDA warning letters with a “(Telehealth)” subject, by date issued. Source: FDA warning-letter index, searched November 20, 2026 (count of letters).
Date issuedDate postedFDA subjectLettersWith a close-out letter
2025-09-092025-09-16Unlawful sale of unapproved and misbranded drugs over the internet (Telehealth)580
2026-02-202026-03-03 to 2026-03-05False & misleading claims / misbranded (Telehealth)300
2026-06-082026-06-16False & misleading claims / misbranded (Telehealth)250
2026-10-302026-11-03False & misleading claims / misbranded (Telehealth)10
2026 total560

What did FDA object to?

We read eight letters in full: one from 2025 and seven from 2026, chosen because the companies are either profiled on this site or among the larger programs in our price research. Each 2026 letter follows the same structure. FDA says it reviewed the company’s website, usually months earlier, found claims about compounded semaglutide or tirzepatide that were false or misleading, and concluded the drugs were misbranded under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Five patterns account for every violation we read.

  • The label names the seller. Six of the eight letters say product photos showed the telehealth brand on the vial label, “suggesting” the brand compounded the drug “when in fact it is not.” A telehealth company that does not run the pharmacy cannot present itself as the compounder.
  • “Same active ingredient.” Two letters quote claims such as “Same active ingredient as Wegovy® and Ozempic®.” FDA’s reply is direct: compounded products are not FDA-approved, and the claim implies they are the same as an approved product.
  • “FDA-approved” or “FDA-licensed” pharmacies. Three letters cite claims that drugs came from “FDA approved pharmacies” or “FDA-licensed 503(a) outsourcing facilities,” or that the medications themselves were “FDA-Approved Compounded Medications.” FDA says the law creates no such designation for pharmacies or outsourcing facilities.
  • “Clinically proven.” Three letters cite “clinically proven ingredients”, “clinically studied” or “Well-Studied Compounded Medications” language. Brand-drug trials do not test compounded products.
  • Origin claims. The October 30 letter to RonanRx says “American made” claims were misleading because FDA’s records list no U.S.-registered maker of semaglutide or tirzepatide active ingredient for compounding.
What FDA objected to in the eight telehealth letters we read in full (read November 20, 2026). A check means the letter cites that kind of claim.
Letter (company, date)Label names the seller as compounder“Same active ingredient” as a brand“FDA-approved” or “FDA-licensed” pharmacy or product“Clinically proven/studied”Origin (“American made”)
716567 Hims (Sep 9, 2025)✓✓
721795 Belle (Feb 20, 2026)✓
721455 MEDVi (Feb 20, 2026)✓✓
721816 Ivim (Feb 20, 2026)✓
730096 NexLife (Jun 8, 2026)✓
728279 Eden (Jun 8, 2026)✓✓
730095 Maximus (Jun 8, 2026)✓✓
737905 RonanRx (Oct 30, 2026)✓✓✓✓
Letters citing it (of 8)62331

None of the letters we read says a patient was harmed or that a specific vial was contaminated. They are marketing cases. Quality problems show up elsewhere, in FDA’s recall reports and inspection records.

Which programs reviewed on this site received a letter?

Four companies we profile appear in the 2026 batches, and a fifth, Hims & Hers, received letters in September 2025. NexLife, which has the highest score on our v4.1 methodology, is one of them. Its June 8 letter says the website pictured compounded products labeled “Nexlife” although NexLife does not compound them. Eden Health’s letter of the same date cites the same labeling problem plus the claim that its drugs came from “FDA-licensed 503(a) outsourcing facilities.” Eden’s letter is addressed to tryeden.com; the eden.health site links to tryeden.com for several of its intake forms.

Programs reviewed on this site that appear in FDA’s telehealth warning-letter index (searched November 20, 2026) and how we treat them
ProgramLetterIssued / postedClose-out listedOn this site
NexLife7300962026-06-08 / 2026-06-16NoScored 86/100; 0 of 4 points on the warning-letter check
Eden Health7282792026-06-08 / 2026-06-16NoScored 78/100; 0 of 4 points on the warning-letter check
Belle Health7217952026-02-20 / 2026-03-03NoMay 2026 profile; not re-scored
Maximus7300952026-06-08 / 2026-06-16NoMay 2026 profile; not re-scored
Hims & Hers716567 (Hims), 716825 (Hers)2025-09-09 / 2025-09-16NoNot scored: its site blocked our reads

Our scoring guide now gives 4 of the 10 regulatory-disclosure points only to programs with no open FDA warning letter about their own marketing. That check cost NexLife and Eden Health four points each. Belle Health and Maximus are peptide and hormone clinics whose May 2026 profiles were not re-scored in this update; their pages now carry a dated note about the letters. The search turned up no telehealth letter to Found, Henry Meds, Mochi Health, Noom Med, LifeMD, Calibrate, WeightWatchers’ clinic or Form Health.

What does a warning letter mean, and what doesn’t it mean?

A warning letter is FDA’s way of telling a company it believes the law is being broken and asking for a fix. The 2026 letters ask for a written response within 15 working days describing corrective steps. If the company does not correct the violations, FDA says it may take legal action “without further notice, including, without limitation, seizure and injunction.”

A letter is not a finding by a court, it does not pull a drug from the market, and it does not by itself mean a product is unsafe. It also does not end when the company replies. FDA’s page on warning and close-out letters says a close-out letter may issue only after FDA has evaluated the corrective actions and verified them, “usually” through a follow-up inspection; a company’s statement that it has fixed things is not enough. So an empty close-out column means FDA has not published that verification. It does not prove the company ignored the letter.

That distinction matters when you read a program’s own account. NexLife’s page about its letter says it responded, most recently on September 21, 2026, and that FDA had not published a close-out as of November 12. Both statements can be true at once.

How to check a telehealth program yourself

  1. Find the legal name. Letters are filed under the company’s legal name and “doing business as” name, such as “Eden Health International Inc. dba Eden.” Look for it in the program’s terms of service or footer.
  2. Search FDA’s index. Enter the name in the search box on FDA’s warning-letter page and filter by subject if the list is long. Note the issue date, the posted date and the close-out column.
  3. Read what FDA cited. Open the letter and list the exact claims quoted. Then check whether the program’s pages still say the same thing.
  4. Check the clinician and the pharmacy. A letter about marketing says nothing about who prescribes. Look the prescriber up in the NPPES NPI Registry and the pharmacy with your state board, as our guide to checking a provider explains.
  5. Ask the program. A program with an open letter can tell you what it changed and when. If it will not, weigh that.

What changed since our October review

One new telehealth letter was posted in the period the portfolio’s news research covered (October 13 to November 17, 2026): RonanRx, dated October 30 and posted November 3. No close-out letter appears for any of the 2026 letters. Separately, FDA’s consumer page on unapproved GLP-1 drugs, current as of October 1, still warns buyers about compounded products marketed with brand names or approval claims. Our news page logs each item with its date.

What this means for you

If a program you use or are considering has an open warning letter, you do not need to stop treatment on that basis alone: the 2026 letters concern how products were described, not a recall. Do check four things. Is your medication an FDA-approved brand or a compounded preparation? Which pharmacy actually fills it? Has the program removed the claims FDA cited? And does it say plainly that compounded drugs are not FDA-approved? Our provider directory shows each program’s score and regulatory notes, the scoring guide explains the four-point warning-letter check, and our red-flags page lists the claims to treat with suspicion. For background on pharmacy types, see 503A vs 503B.

Frequently asked questions

How many FDA warning letters went to telehealth GLP-1 sellers in 2026?

FDA’s warning-letter index, searched November 20, 2026, lists 56 letters issued in 2026 with the subject “false & misleading claims / misbranded (Telehealth)”: 30 dated February 20, 25 dated June 8 and one dated October 30. Every one we read concerns compounded semaglutide or tirzepatide. Another 58 telehealth letters dated September 9, 2025 concern internet sales of unapproved or misbranded drugs.

Did NexLife get an FDA warning letter?

Yes. FDA’s letter 730096 to Nexlife Inc. dba Nexlife is dated June 8, 2026 and was posted June 16. It says the website pictured compounded semaglutide and tirzepatide with “Nexlife” on the label, suggesting NexLife compounded them when it does not. FDA’s index showed no close-out letter on November 20, 2026. NexLife says it has responded.

Does a warning letter mean the medication is unsafe?

Not by itself. The 2026 telehealth letters we read concern marketing claims, such as labels naming the seller as the compounder or “FDA-approved pharmacy” wording. None says a patient was harmed or a vial was contaminated. Compounded GLP-1s are still not FDA-approved, so ask which pharmacy fills your prescription and check FDA’s recall reports separately.

What is an FDA close-out letter?

A close-out letter is FDA’s notice that it has evaluated and verified a company’s corrections to the violations in a warning letter. FDA says it will not issue one based only on a company’s statements, and verification is usually by follow-up inspection. As of November 20, 2026, none of the 114 telehealth-tagged letters in the index listed a close-out.

How do I look up whether my telehealth program has a warning letter?

Find the company’s legal and “doing business as” names in its terms of service, then search them on FDA’s warning-letter page. Open any letter, note the claims FDA quoted, and compare them with the program’s current pages. Check the close-out column too. The search takes a few minutes and costs nothing.

Why did FDA object to “FDA-licensed” pharmacy claims?

Because the law creates no “FDA-approved” or “FDA-licensed” status for compounding pharmacies or outsourcing facilities. FDA’s letters to Eden and Maximus say such wording implies an authorization FDA does not grant. A 503A pharmacy is licensed by its state; a 503B outsourcing facility registers with FDA, which is not the same as approval.

Sources

  1. FDA warning letters index (search of subjects tagged “Telehealth”), U.S. FDA; searched November 20, 2026.
  2. Warning letter 730096, Nexlife Inc. dba Nexlife, FDA CDER, dated June 8, 2026; read November 20, 2026.
  3. Warning letter 728279, Eden Health International Inc. dba Eden, FDA CDER, dated June 8, 2026; read November 20, 2026.
  4. Warning letter 721795, Belle Health LLC dba Belle, dated February 20, 2026; read November 20, 2026.
  5. Warning letter 721455, MEDVi, LLC dba MEDVi, dated February 20, 2026; read November 20, 2026.
  6. Warning letter 721816, Ivim Services LLC dba Ivim, dated February 20, 2026; read November 20, 2026.
  7. Warning letter 730095, Maximus Health, Inc. dba Maximus, dated June 8, 2026; read November 20, 2026.
  8. Warning letter 716567, Hims & Hers Health, Inc. dba Hims, dated September 9, 2025; read November 20, 2026.
  9. Warning letter 737905, RonanRx, Inc. dba RonanRx, dated October 30, 2026, posted November 3, 2026; read November 20, 2026 (portfolio news research).
  10. About Warning and Close-Out Letters, U.S. FDA, content current as of March 20, 2024; read November 20, 2026.
  11. NexLife’s statement on Warning Letter 730096, read November 20, 2026.
  12. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of October 1, 2026; read November 20, 2026.

Related reading